Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
BioCon
BioCon
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Ingredients
Biocon collaborates to commercialise generic formulas in South East Asia
Biocon Pharma and DKSH Business Unit Healthcare have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma's generic formulations in Singapore and Thailand
Biocon appoints new CEO
Siddharth Mittal has taken over from Dr Arun Chandavarkar as CEO & Joint Managing Director of India-based Biocon
Regulatory
Biocon biologics facility gets FDA nod
India's biopharmaceutical giant has been investing in expanding manufacturing capacity in line with expectations of higher biosimilars penetration in developed and emerging market
Ingredients
Biocon recieves GMP status for Malaysian insulin facility
Indian Biocon’s Malaysia facility manufactures drug substance and drug products in vials, cartridges and insulin delivery devices
Finance
Biocon strikes up MYR 300 million ($68m) contract for insulin with Malaysia
Malaysia's Ministry of Health three-year contract for rh-Insulin will reduce its reliance on imports
Regulatory
Delhi High Court puts restrictions on Biocon and Mylan breast cancer drug marketing
Court allowed the sale and manufacture of affordable cancer drugs by Biocon and Mylan with certain restrictions on packaging and labelling and regulatory process
Regulatory
Biocon's partnership with Mylan makes significant progress
Biocon will be filing for regulatory approvals in key developed markets in a phased manner during 2016 for four biosimilars
Subscribe now